Omicron was founded by Søren Lophaven in August 2019 and aims at delivering top quality consultancy within biostatistics, statistical programming, epidemiology, real-world evidence and register-based research. I work with pharmaceutical companies, biotech and medical device companies and public institutions in Denmark, and collaborate with Damvad Analytics within the area of Real-world evidence. Omicron is a member of the Danish Society for Biopharmaceutical Statistics. I am financially supporting the R-project and will continue to promote the use of R in clinical development and epidemiology.
Our manuscript entitled "Outcomes in GLP-1 RA-experienced patients switching to once-weekly semaglutide in a real-world setting: The retrospective, observational EXPERT study" was published in Diabetes Therapy. Learn More.
I am giving a presentation about data management and statistics in clinical trials at atrium.
Our manuscript entitled "Disease activity patterns, mortality and colorectal cancer risk in microscopic colitis: a Danish nationwide cohort study, 2001 to 2016" was published in Journal of Crohns and Colitis. Learn More.
Our manuscript entitled "Incidence and prevalence of microscopic colitis between 2001 and 2016: A Danish nationwide cohort study" was published in Journal of Crohns and Colitis. Learn More.
Our manuscript entitled "High incidence of dementia in Faroese-born female residents in Denmark" was published in Alzheimer's & Dementia: Translational Research & Clinical Interventions. Learn More.
I am attending the celebRation workshop to mark the 20th anniversary of the release of R version 1.0.0.
I am attending the annual meeting of the Danish Society for Pharmacoepidemiology: The clinical implications of pharmacoepidemiological research.